



## **argenx to Present at Goldman Sachs 45<sup>th</sup> Annual Global Healthcare Conference**

**June 4, 2024**

**Amsterdam, the Netherlands** – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45<sup>th</sup> Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET in Miami, FL.

A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at [argenx.com/investors](https://www.argenx.com/investors). A replay of the webcast will be available on the argenx website for approximately 90 days following the fireside chat.

### **About argenx**

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit [www.argenx.com](https://www.argenx.com) and follow us on [LinkedIn](#), [X/Twitter](#), [Instagram](#), [Facebook](#), and [YouTube](#).

**For further information, please contact:**

#### **Media:**

Ben Petok  
[bpetok@argenx.com](mailto:bpetok@argenx.com)

#### **Investors:**

Alexandra Roy (US)  
[aroy@argenx.com](mailto:aroy@argenx.com)

Lynn Elton (EU)  
[lelton@argenx.com](mailto:lelton@argenx.com)